Antimicrobial activities of trimethoprim/sulfamethoxazole, 5-iodo-2'-deoxyuridine and rifampicin against Staphylococcus aureus

International Journal of Antimicrobial Agents

Volumn 36, Issue 6, 2010, Pages 562-565

  Zander, Johannes ^a   Besier, Silke ^a   Faetke, Sebastian ^a   Saum, Stephan H ^b   Müller, Volker ^b   Wichelhaus, Thomas A ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

5 Iodo 2' deoxyuridine; Antimicrobial activity; Rifampicin; Thymidine; Trimethoprim sulfamethoxazole

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; IDOXURIDINE; RIFAMPICIN; THYMIDINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG POTENTIATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTIC FIBROSIS; DRUG INTERACTIONS; HUMANS; IDOXURIDINE; MICROBIAL SENSITIVITY TESTS; RIFAMPIN; SPUTUM; STAPHYLOCOCCUS AUREUS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 78249248677     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.08.007     Document Type: Article

References (15)

1. Stone A., Saiman L. Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis. Curr Opin Pulm Med 2007, 13:515-521.
2. Ellis M.W., Lewis J.S. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 2005, 18:496-501.
3. Proctor R.A. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008, 46:584-593.
4. Zander J., Besier S., Ackermann H., Wichelhaus T.A. Synergistic antimicrobial activities of folic acid antagonists and nucleoside analogs. Antimicrob Agents Chemother 2010, 54:1226-1231.
5. Nathwani D., Morgan M., Masterton R.G., Dryden M., Cookson B.D., French G., et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 2008, 61:976-994.
6. Alvarez S., DeMaria A., Kulkarni R., Klein J.O., McCabe W.R. Interactions of rifampin and trimethoprim in vitro. Rev Infect Dis 1982, 4:390-401.
7. Kaka A.S., Rueda A.M., Shelburne S.A., Hulten K., Hamill R.J., Musher D.M. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006, 58:680-683.
8. Besier S., Zander J., Siegel E., Saum S.H., Hunfeld K.P., Ehrhart A., et al. Thymidine-dependent Staphylococcus aureus small-colony variants: human pathogens that are relevant not only in cases of cystic fibrosis lung disease. J Clin Microbiol 2008, 46:3829-3832.
9. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M7-A8. Wayne, PA: CLSI; 2008.
10. Clinical and Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. Wayne, PA: CLSI; 1999.
11. Kumar A., Khan I.A., Koul S., Koul J.L., Taneja S.C., Ali I., et al. Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus. J Antimicrob Chemother 2008, 61:1270-1276.
12. Besier S., Smaczny C., von Mallinckrodt C., Krahl A., Ackermann H., Brade V., et al. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol 2007, 45:168-172.
13. Grueneberg R.N., Emmerson A.M. Prevention of emergence of bacterial resistance by combination of two antibiotics: rifampicin and trimethoprim. J Antimicrob Chemother 1980, 6:349-356.
14. Harvey R.J. Antagonistic interaction of rifampicin and trimethoprim. J Antimicrob Chemother 1978, 4:315-327.
15. Galanis E., Goldberg R., Reid J., Atherton P., Sloan J., Pitot H., et al. Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd). Ann Oncol 2001, 12:701-707.